Clinical Trial: Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Treatment Resistant Schizophrenia
Study Type: INTERVENTIONAL
Official Title: Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia: A Randomized, Group Sequential Adaptive Design, Controlled Clinical Trial
Brief Summary:
Dextromethorphan acts as N-methyl-D-aspartate (NMDA) antagonist.In Treatment resistant schizophrenia(TRS) the efficacy of treatment response by clozapine is only around 40%.Numerous augmentation agent have been tried which includes antipsychotics, anticonvulsants, antidepressants and NMDA antagonist.The NMDA antagonist such as Riluzole and Memantine have shown good efficacy in TRS.Therefore we are evaluating NMDA antagonist, dextromethorphan in TRS.The dextromethorphan or placebo will be administered along with…
Read more